References

 

1.     Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Hörsch D, O’Dorisio MS, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013;40:800–16. https://doi.org/10.1007/s00259-012-2330-6.

2.     Kwekkeboom DJ, Krenning EP, Lebtahi R, Komminoth P, Kos-Kudła B, de Herder WW, et al. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Peptide Receptor Radionuclide Therapy with Radiolabelled  Somatostatin Analogue s. Neuroendocrinology 2009;90:220–226. https://doi.org/10.1159/000225951.

3.     Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjogreen-Gleisner K, et al. MIRD Pamphlet No. 26: Joint EANM/MIRD Guidelines for Quantitative 177Lu SPECT Applied for Dosimetry of Radiopharmaceutical Therapy. Journal of Nuclear Medicine 2016;57:151–162. 10.2967/jnumed.115.159012 

4.     Sandström M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate. European Journal of Nuclear Medicine and Molecular Imaging 2010;37:212–225. https://doi.org/10.1007/s00259-009-1216-8.

5.     Hebert K, Santoro L, Monnier M, Castan F, Berkane I, Assénat E, Fersing C, Gélibert P, Pouget JP, Bardiès M, Kotzki PO, Deshayes E. Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumours Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine. J Nucl Med. 2024 Jun 3;65(6):923-930. doi: 10.2967/jnumed.123.267023.

6.     Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose Response of Pancreatic Neuroendocrine Tumours Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE. Journal of Nuclear Medicine 2015;56:177–182. https://doi.org/10.2967/jnumed.114.148437.

7.     Sundlöv, A., Gleisner, K., Tennvall, J. et al. Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients.Eur J Nucl Med Mol Imaging 49, 3830–3840 (2022). doi: 10.1007/s00259-022-05786-w.

8.     Warfvinge CF, Gustafsson J, Roth D, Tennvall J, Svensson J, Bernhardt P, Åkesson A, Wieslander E, Sundlöv A, Sjögreen Gleisner K. Relationship Between Absorbed Dose and Response in Neuroendocrine Tumours Treated with [177Lu]Lu-DOTATATE. J Nucl Med. 2024 Jul 1;65(7):1070-1075. doi: 10.2967/jnumed.123.266991.

9.     Pavel M, O’Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology 2016;103:172–85. https://doi.org/10.1159/000443167.

10.     Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumours. New England Journal of Medicine 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427.

11.     Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumours. Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743.

12.     Ilan E, Sandstrom M, Wassberg C, Sundin A, Garske-Roman U, Eriksson B, et al. Dose Response of Pancreatic Neuroendocrine Tumours Treated with Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE. Journal of Nuclear Medicine 2015;56:177–182. https://doi.org/10.2967/jnumed.114.148437. 

13.     Singh S, Halperin D, Myrehaug S, Herrmann K, Pavel M, Kunz PL, Chasen B, Tafuto S, Lastoria S, Capdevila J, García-Burillo A, Oh DY, Yoo C, Halfdanarson TR, Falk S, Folitar I, Zhang Y, Aimone P, de Herder WW, Ferone D; all the NETTER-2 Trial Investigators. [177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high-dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study. Lancet. 2024 Jun 29;403(10446):2807-2817. doi: 10.1016/S0140-6736(24)00701-3

14.     Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E; NETTER-1 Trial Investigators. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumours. N Engl J Med. 2017 Jan 12;376(2):125-135. doi: 10.1056/NEJMoa1607427

15.     Sandstrom M, Garske-Roman U, Granberg D, Johansson S, Widstrom C, Eriksson B, et al. Individualized Dosimetry of Kidney and Bone Marrow in Patients Undergoing 177Lu-DOTA-Octreotate Treatment. Journal of Nuclear Medicine 2013;54:33–41. https://doi.org/10.2967/jnumed.112.107524.

16.     Garkavij M, Nickel M, Sjögreen-Gleisner K, Ljungberg M, Ohlsson T, Wing\a ardh K, et al. 177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumours: Analysis of dosimetry with impact on future therapeutic strategy. Cancer 2010;116:1084–1092. https://doi.org/10.1002/cncr.24796. 

17.     Bergsma H, Konijnenberg MW, Kam BLR, Teunissen JJM, Kooij PP, de Herder WW, et al. Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course. European Journal of Nuclear Medicine and Molecular Imaging 2016;43:453–463. https://doi.org/10.1007/s00259-015-3193-4. 

18.     Bergsma H, van Lom K, Raaijmakers MHGP, Konijnenberg M, Kam BLBLR, Teunissen JJM, et al. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE: Incidence, Course, and Predicting Factors in Patients with Gastroenteropancreatic Neuroendocrine Tumours. Journal of Nuclear Medicine 2018;59:452–458. https://doi.org/10.2967/jnumed.117.189712. 

19.     Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, van Eijck CHJ, Franssen GJH, Krenning EP, Kwekkeboom DJ. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumours. Clin Cancer Res. 2017 Aug 15;23(16):4617-4624. doi: 10.1158/1078-0432.CCR-16-2743

20.     Grozinsky-Glasberg S, Davar J, Hofland J, Dobson R, Prasad V, Pascher A, Denecke T, Tesselaar MET, Panzuto F, Albåge A, Connolly HM, Obadia JF, Riechelmann R, Toumpanakis C. European Neuroendocrine Tumour Society (ENETS) 2022 Guidance Paper for Carcinoid Syndrome and Carcinoid Heart Disease. J Neuroendocrinol. 2022 Jul;34(7):e13146. doi: 10.1111/jne.13146.)

21.     Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. European Journal of Nuclear Medicine and Molecular Imaging 2003;30:510–518. https://doi.org/10.1007/s00259-003-1117-1. 

22.     Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabelled  Somatostatin Analogue ue [90 Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers. Journal of Clinical Oncology 2011;29:2416–2423. https://doi.org/10.1200/JCO.2010.33.7873. 

23.     Minarik D, Sjögreen-Gleisner K, Linden O, Wing\a ardh K, Tennvall J, Strand S-E, et al. 90Y Bremsstrahlung imaging for absorbed-dose assessment in high-dose radioimmunotherapy. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2010;51:1974–8. https://doi.org/10.2967/jnumed.110.079897. 

24.     Walrand S, Jamar F, Van Elmbt L, Lhommel R, Bidja ’a Bekonde E, Pauwels S. 4-Step Renal Dosimetry Dependent on Cortex Geometry Applied to 90 Y Peptide Receptor Radiotherapy: Evaluation Using a Fillable Kidney Phantom Imaged by 90 Y PET. J Nucl Med 2010;51:1969–1973. https://doi.org/10.2967/jnumed.110.080093. 

25.     Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging 2008;35:1847–56. https://doi.org/10.1007/s00259-008-0778-1. 

26.     Walrand S, Jamar F, Mathieu I, Camps J, Lonneux M, Sibomana M, et al. Quantitation in PET using isotopes emitting prompt single gammas: application to yttrium-86. European Journal of Nuclear Medicine and Molecular Imaging 2003;30:354–361. https://doi.org/10.1007/s00259-002-1068-y. 

27.     Kletting P, Müller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Medical Physics 2012;39:5708–5717. https://doi.org/10.1118/1.4747266. 

28.     Hindorf C, Chittenden S, Causer L, Lewington VJ, Mäcke HR, Flux GD. Dosimetry For 90Y-DOTATOC Therapies in Patients with Neuroendocrine Tumours. Cancer Biotherapy & Radiopharmaceuticals 2007;22:130–135. https://doi.org/10.1089/cbr.2007.306. 

29.     Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90 Y-Labeled Somatostatin Analogue s n.d. 15653657

30.     Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. European Journal of Nuclear Medicine and Molecular Imaging 2015;42:5–19. https://doi.org/10.1007/s00259-014-2893-5. 

31.     Binnebeek SV, Baete K, Vanbilloen B, Terwinghe C, Koole M, Mottaghy FM, et al. Individualized dosimetry-based activity reduction of 90 Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging n.d. https://doi.org/10.1007/s00259-013-2670-x. 

32.     Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2005;46 Suppl 1:83S–91S. 15653656.

33.     Walrand S, Barone R, Pauwels S, Jamar F. Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts. European Journal of Nuclear Medicine and Molecular Imaging 2011;38:1270–1280. https://doi.org/10.1007/s00259-011-1744-x. 

34.     Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort Study of Somatostatin-Based Radiopeptide Therapy With [90 Y-DOTA]-TOC Versus [90 Y-DOTA]-TOC Plus [177 Lu-DOTA]-TOC in Neuroendocrine Cancers. Journal of Clinical Oncology 2012;30:1100–1106. https://doi.org/10.1200/JCO.2011.37.2151. 

35.     Kunikowska J, Królicki L, Hubalewska-Dydejczyk A, Miko\lajczak R, Sowa-Staszczak A, Pawlak D. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? European Journal of Nuclear Medicine and Molecular Imaging 2011;38:1788–1797. https://doi.org/10.1007/s00259-011-1833-x. 

36.     Eckerman, K, Menzel, H. In the book of life, the answers aren’t in the back - Charlie Brown, fictional character of the Peanuts comic strip created by Charles Schulz: Annals of the ICRP 2008. https://doi.org/10.1016/j.icrp.2009.02.001.

37.     Pauwels S, Barone R, Walrand S, Borson-Chazot F, Valkema R, Kvols LK, et al. Practical Dosimetry of Peptide Receptor Radionuclide Therapy with 90Y-Labeled Somatostatin Analogue s. J Nucl Med 2005;46:92S-98S. PMID: 15653657

38.     Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2005;46 Suppl 1:99S–106S. PMID: 15653658

39.     Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response–Implications for Radionuclide Therapy. Journal of Nuclear Medicine 2008;49:1884–1899. https://doi.org/10.2967/jnumed.108.053173. 

40.     Sgouros G. Alpha-particles for targeted therapy. Adv Drug Deliv Rev. 2008;60(12):1402–1406. https://doi.org/10.1016/j.addr.2008.04.007 

41.     ES Delpassand, I Tworowska, R Esfandiari, J Torgue, J Hurt, A Shafie, et al. Targeted α -Emitter Therapy with 212 Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumours: First-in-Humans Dose-Escalation Clinical Trial J Nucl Med, 63 (9) (2022), pp. 1326-1333, 10.2967/jnumed.121.263230;

42.    Miederer M, Scheinberg DA, McDevitt MR. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Adv Drug Deliv Rev. 2008;60(12):1371–1382. https://doi.org/10.1016/j.addr.2008.04.009.

43.    Demirci E, Alan Selçuk N, Beydağı G, Ocak M, Toklu T, Akçay K, Kabasakal L. Initial Findings on the Use of [225Ac]Ac-DOTATATE Therapy as a Theranostic Application in Patients with Neuroendocrine Tumours. Mol Imaging Radionucl Ther. 2023 Oct 20;32(3):226-232. doi: 10.4274/mirt.galenos.2023.38258

44.     Vorster M, Grana CM, Travascio L, Sathekge MM. Alpha therapies: where and when is the future in neuroendocrine tumours? Clinical and Translational Imaging (2025) 13:329–337 

45.     Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP; NETTER-1 investigators. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec;22(12):1752-1763. doi: 10.1016/S1470-2045(21)00572-6

46.     Delpassand ES, Tworowska I, Esfandiari R, Torgue J, Hurt J, Shafie A, Núñez R. Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumours: First-in-Humans Dose-Escalation Clinical Trial. J Nucl Med. 2022 Sep;63(9):1326-1333. doi: 10.2967/jnumed.121.263230

47.     Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, Kwekkeboom DJ. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12. doi: 10.1007/s00259-011-2039-y.

48.     Bodei L, Cremonesi M, Ferrari M, Mittra ES, Kulkarni HR, Deroose CM, Srirajaskanthan R, Ramage J, Grana CM, Botta F, Weber MM, Miederer M, Reddy R, Chicco D, Mariani MF, Demange A, Erion JL, Gericke G, Krenning E. Dosimetry of [177Lu]Lu-DOTATATE in Patients with Advanced Midgut Neuroendocrine Tumours: Results from a Substudy of the Phase III NETTER-1 Trial. J Nucl Med. 2025 Mar 3;66(3):449-456. doi: 10.2967/jnumed.124.268903.

49.     Y-90 Tables [Internet]. Available from: http://www.lnhb.fr/nuclides/Y-90_tables.pdf